Does Rallies show 13F holders for IFRX?

Yes. Rallies tracks hedge fund and 13F ownership data for IFRX, including fund names, share counts, latest tracked quarter, and position changes when available.

Is IFRX research on Rallies investment advice?

No. Rallies provides research, data, and educational context for IFRX. It does not provide personalized investment advice.

IFRX (InflaRx N.V. Common Stock) Stock Analysis - Hedge Fund Holdings

InflaRx N.V. Common Stock (IFRX) is a publicly traded Healthcare sector company. As of May 21, 2026, IFRX trades at $2.41 with a market cap of $368.23M and a P/E ratio of 0.00. IFRX moved +2.95% today. Year to date, IFRX is +114.03%; over the trailing twelve months it is +37.85%. Its 52-week range spans $0.71 to $2.95. Analyst consensus is strong buy with an average price target of $8.00. Rallies surfaces IFRX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns IFRX stock?

Hedge funds tracked by Rallies that own IFRX include Citadel Advisors, Two Sigma, and Two Sigma. The latest tracked quarter is Dec 31, 2024. Rallies shows current holdings, share counts, position changes, and 13F ownership context for InflaRx N.V. Common Stock.

IFRX Key Metrics

Key financial metrics for IFRX
Metric	Value
Price	$2.41
Market Cap	$368.23M
P/E Ratio	0.00
EPS	$0.00
Dividend Yield	0.00%
52-Week High	$2.95
52-Week Low	$0.71
Volume	30
Avg Volume	0
Revenue (TTM)	$0
Net Income	$0
Gross Margin	0.00%

Top Hedge Funds Holding IFRX

Citadel Advisors holds 50.91K shares of IFRX, changed +121.93% as of Dec 31, 2024.
Two Sigma holds 19.72K shares of IFRX, changed -17.89% as of Dec 31, 2024.
Two Sigma holds 11.46K shares of IFRX, changed -5.05% as of Dec 31, 2024.

Latest IFRX News

InflaRx closes $150 million equity offering: 75 million shares at $2 each — May 8, 2026
InflaRx Secures Funding Through 2029, Advances Izicopan in AAV and Renal Diseases — May 6, 2026
Izicopan Shows Over 100-Fold Lower Reactive Metabolite Formation Than Avacopan — May 4, 2026
InflaRx Shares Top $1 for 10 Days to Regain Nasdaq Compliance — Apr 28, 2026
Izicopan Shows No CYP3A4 Inhibition at >100 µM, No Time-Dependent DDIs — Apr 9, 2026

Recent IFRX Insider Trades

Parliament Scott B sold 5.00K (~$1.30K) on Feb 25, 2008.
Parliament Scott B sold 2.70K (~$891) on Feb 19, 2008.

IFRX Analyst Consensus

6 analysts cover IFRX: 0 strong buy, 5 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $8.00.

Common questions about IFRX

Who owns IFRX stock?: Hedge funds tracked by Rallies that own IFRX include Citadel Advisors, Two Sigma, and Two Sigma. The latest tracked quarter is Dec 31, 2024. Rallies shows current holdings, share counts, position changes, and 13F ownership context for InflaRx N.V. Common Stock.
Does Rallies show 13F holders for IFRX?: Yes. Rallies tracks hedge fund and 13F ownership data for IFRX, including fund names, share counts, latest tracked quarter, and position changes when available.
Is IFRX research on Rallies investment advice?: No. Rallies provides research, data, and educational context for IFRX. It does not provide personalized investment advice.